Year : 2021 | Volume
: 15 | Issue : 4 | Page : 377--382
Assessment of pain in patients with primary immune deficiency
Maram Al Banyan1, Saad Al Shareef1, Dina Mahmoud Ahmad Aljayar2, Fayha Farraj Abothenain2, Agha M Rehan Khaliq3, Hassan Alrayes1, Rand Arnaout3, Farrukh Sheikh1
1 Department of Medicine, Section of Allergy and Immunology, King Faisal Specialist Hospital and Research Centre, Riyadh, Kingdom of Saudi Arabia
2 Alfaisal University, Riyadh, Kingdom of Saudi Arabia
3 Department of Medicine, Section of Allergy and Immunology, King Faisal Specialist Hospital and Research Centre; Alfaisal University, Riyadh, Kingdom of Saudi Arabia
Background: Primary immune deficiency (PID) patients may develop acute or chronic pain. Pain has not been studied in this population until now.
Objectives: This study systematically assessed the pain of various durations in PID patients using validated pain questionnaires.
Subjects and Methods: A Short-Form McGill Pain Questionnaire (SF-MPQ), already validated in the Arabic language, was used to ascertain the characteristics and severity of pain. Additionally, an Arabic version of the Neuropathic Pain Questionnaire-Short Form (NPQ-SF) was employed to evaluate neuropathic pain in the same group of patients.
Results: Forty-six patients participated in the study. The mean age of the patients was 25 years. The most commonly diagnosed PID was a common variable immune deficiency (32.6%), followed by severe combined immune deficiency (19.57%). Based on the SF-MPQ, the pain was experienced by 30.4 % of the subjects who participated in the study; 57% of whom were on regular pain medications. The most common site reported for pain was the abdomen (35.7%). The mean duration of pain was 36.1 days ± 34.6 days. The most common comorbidities in these patients were bronchiectasis, followed by immune thrombocytopenic purpura, and scoliosis. None of the PID patients had significant neuropathic pain based on NFQ-SF.
Conclusion: To the best of our knowledge, this is the first study to assess the prevalence as well as the severity and duration of pain in PID patients. There were significantly more subjects who had continuous pain. Treatment of pain in PID patients will have a significant effect on improving their quality of life.
Maram Al Banyan
Department of Medicine, Section of Allergy and Immunology, King Faisal Specialist Hospital and Research Centre, P. O. Box3354, Riyadh – 11211
Kingdom of Saudi Arabia
|How to cite this article:|
Al Banyan M, Al Shareef S, Aljayar DM, Abothenain FF, Khaliq AM, Alrayes H, Arnaout R, Sheikh F. Assessment of pain in patients with primary immune deficiency.Saudi J Anaesth 2021;15:377-382
|How to cite this URL:|
Al Banyan M, Al Shareef S, Aljayar DM, Abothenain FF, Khaliq AM, Alrayes H, Arnaout R, Sheikh F. Assessment of pain in patients with primary immune deficiency. Saudi J Anaesth [serial online] 2021 [cited 2021 Dec 1 ];15:377-382
Available from: https://www.saudija.org/article.asp?issn=1658-354X;year=2021;volume=15;issue=4;spage=377;epage=382;aulast=Al;type=0